Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial
European Journal of Cancer · 2026-08 · 244 · 116903
DOI: 10.1016/j.ejca.2026.116903 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Dong Ho Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, South Korea; Institute of Radiation Medic…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Ministry of Trade, Industry and Energy, Focused Ultrasound Foundation, Ministry of Health and Family Welfare.
Abstract (Originalsprache)
INTRODUCTION: FOLFIRINOX is standard chemotherapy for borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC), but response rates remain suboptimal. Mechanical effect-dominant non-thermal focused ultrasound (FUS) may enhance drug delivery. This study prospectively evaluated the safety and efficacy of FUS plus FOLFIRINOX in patients with BRPC or LAPC. METHODOLOGY: In this exploratory phase II trial (NCT05262452), participants with BRPC or LAPC received FUS plus FOLFIRINOX chemotherapy during the first four cycles, followed by FOLFIRINOX continuation. The primary endpoint was objective response rate (ORR); secondary endpoints included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. A propensity score matched historical cohort of patients treated with FOLFIRINOX alone served as a control group. RESULTS: Of 60 enrolled patients, 56 completed four cycles of combined therapy and were matched to 56 FOLFIRINOX-only controls. ORR was higher with FUS plus FOLFIRINOX than with FOLFIRINOX alone (64.3% vs. 35.7%; P = 0.003). Median OS was 24.0 versus 17.0 months (hazard ratio [HR], 0.63; 95% CI, 0.41-0.97; P = 0.029), and median PFS was 16.0 versus 11.0 months (HR, 0.65; 95% CI, 0.43-0.99; P = 0.039) for FUS plus FOLFIRINOX and FOLFIRINOX-only groups, respectively. Grade ≥ 3 toxicities occurred in 55.4% and 57.1% of patients (P = 0.849), with no FUS-related or collateral organ injuries. DISCUSSION: Mechanical effect-dominant non-thermal FUS combined with FOLFIRINOX improved response rate and survival outcome without increasing toxicity compared with FOLFIRINOX alone in BRPC or LAPC. These exploratory findings support further evaluation in randomized phase III trials. TRIAL REGISTRATION: This study is registered at clinicaltrials.gov (study identifier: NCT05262452).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, South Korea; Institute of Radiation Medicine, Seoul National University College of Medicine, South Korea.
- Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, South Korea; Institute of Radiation Medicine, Seoul National University College of Medicine, South Korea. Elect…
- Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, South Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, South Korea. Electronic address: gidoctor@snu.ac.kr.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, South Korea.
- Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, South Korea.
Förderung
- Ministry of Trade, Industry and Energy
- Focused Ultrasound Foundation
- Ministry of Health and Family Welfare
- Korea Medical Device Development Fund
- Korea Ministry of Science and ICT
- Ministry of Food and Drug Safety
Zitieren
APA
Lee, D. H., Lee, J. Y., Kang, S. Y., Lee, S. H., Paik, W. H., Cho, I. R., Kwon, W., & Jang, J. Y. (2026). Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. European Journal of Cancer, 244, 116903. https://doi.org/10.1016/j.ejca.2026.116903
Vancouver
Lee DH, Lee JY, Kang SY, Lee SH, Paik WH, Cho IR, et al. Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. European Journal of Cancer. 2026;244:116903. doi:10.1016/j.ejca.2026.116903
BibTeX
@article{Lee2026,
author = {Lee, Dong Ho and Lee, Jae Young and Kang, Soo Yeon and Lee, Sang Hyub and Paik, Woo Hyun and Cho, In Rae and Kwon, Wooil and Jang, Jin-Young},
title = {Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial},
journal = {European Journal of Cancer},
year = {2026},
volume = {244},
pages = {116903},
doi = {10.1016/j.ejca.2026.116903}
}
EUVIMED